{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T05:50:30Z","timestamp":1681797030058},"reference-count":22,"publisher":"FapUNIFESP (SciELO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p>Summary  Introduction: In patients with essential thrombocythemia (ET), the vascular complications contribute to morbidity and mortality. To better predict the occurrence of thrombotic events, an International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET-thrombosis) has recently been proposed. We present the application of this score and compare its results with the usual classification system.  Method: We retrospectively evaluated the characteristics and risk factors for thrombosis of 46 patients with a diagnosis of ET seen in the last 6 years at Faculdade de Medicina do ABC (FMABC).  Results: Thrombosis in the arterial territory was more prevalent than in venous sites. We observed that cardiovascular risk factors (hypertension, hypercholesterolemia, diabetes mellitus, and smoking) were also risk factors for thrombosis (p&lt;0.001). Age over 60 years and presence of JAK2 V617F mutation were not associated with the occurrence of thrombotic events. No patient classified by IPSET-thrombosis as low risk had a thrombotic event. Furthermore, using the IPSET-thrombosis scale, we identified two patients who had thrombotic events during follow-up and were otherwise classified in the low-risk group of the traditional classification. Leukocytosis at diagnosis was significantly associated with arterial thrombosis (p=0.02), while splenomegaly was associated with venous thrombotic events (p=0.01).  Conclusion: Cardiovascular risk factors and leukocytosis were directly associated with arterial thrombosis. IPSET-thrombosis appears to be better than the traditional classification at identifying lower risk patients who do not need specific therapy.<\/jats:p>","DOI":"10.1590\/1806-9282.62.07.647","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T16:32:14Z","timestamp":1480523534000},"page":"647-651","source":"Crossref","is-referenced-by-count":3,"title":["Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service"],"prefix":"10.1590","volume":"62","author":[{"given":"Luana Magalh\u00e3es","family":"Navarro","sequence":"first","affiliation":[{"name":"Hospital Israelita Albert Einstein,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damila Cristina","family":"Trufelli","sequence":"additional","affiliation":[{"name":"Hospital de Ensino Padre Anchieta,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora Rodrigues","family":"Bonito","sequence":"additional","affiliation":[{"name":"Hospital Estadual M\u00e1rio Covas,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auro","family":"Del Giglio","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina do ABC,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia Weinschenker","family":"Bollmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12032-014-0231-1","article-title":"The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia","volume":"31","author":"Lekovic D","year":"2014","journal-title":"Med Oncol"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman JW","year":"2009","journal-title":"Blood"},{"issue":"16","key":"ref3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Longterm survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi A","year":"2014","journal-title":"Blood"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj AP","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"25","key":"ref5","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMe1313643","article-title":"Another piece of the myeloproliferative neoplasms puzzle","volume":"369","author":"Levine R","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi A","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi E","year":"2014","journal-title":"Blood"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/leu.2014.250","article-title":"Clinical end points for drug treatment trials in BCR-ABL1 negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)","volume":"29","author":"Barosi G","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/187152571201141201092923","article-title":"Novel oral anticoagulants in the management of polycythemia vera and essential thrombocythemia","volume":"12","author":"Karali V","year":"2014","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"26","key":"ref10","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui T","year":"2012","journal-title":"Blood"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ejh.12381","article-title":"Target hematologic values in the management of essential thrombocythemia and polycythemia vera","volume":"94","author":"Hern\u00e1ndez-Boluda JC","year":"2015","journal-title":"Eur J Haematol"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/leu.2013.99","article-title":"Personalized management of essential thrombocythemia - application of recent evidence to clinical practice","volume":"27","author":"Tefferi A","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi A","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui T","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ajh.23135","article-title":"Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Tefferi A","year":"2012","journal-title":"Am J Hematol"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/ejh.12275","article-title":"External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients","volume":"92","author":"Fu R","year":"2014","journal-title":"Eur J Haematol"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"135","author":"Borowczyk M","year":"2015","journal-title":"Thromb Res"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger H","year":"2013","journal-title":"Blood"},{"issue":"22","key":"ref19","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia an international study of 891 patients","volume":"117","author":"Carobbio A","year":"2011","journal-title":"Blood"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.23685","article-title":"Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients","volume":"89","author":"Montanaro M","year":"2014","journal-title":"Am J Hematol"},{"issue":"3-4","key":"ref21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2739\/kurumemedj.MS63001","article-title":"Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms","volume":"60","author":"Takata Y","year":"2014","journal-title":"Kurume Med J"},{"issue":"Suppl 1","key":"ref22","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.clml.2011.01.002","article-title":"Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis","volume":"11","author":"Passamonti F","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v62n7\/0104-4230-ramb-62-07-0647.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T21:54:45Z","timestamp":1495576485000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302016000700647&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0104-42302016000700647"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.62.07.647","relation":{},"ISSN":["0104-4230"],"issn-type":[{"value":"0104-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}